Dexpramipexole dihydrochloride is under clinical development by Areteia Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dexpramipexole dihydrochloride’s likelihood of approval (LoA) and phase transition for Hypereosinophilic Syndrome took place on 18 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dexpramipexole dihydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dexpramipexole dihydrochloride overview

Dexpramipexole dihydrochloride (BIIB050, KNS760704) is under development for the treatment of hypereosinophilic syndrome and eosinophilic asthma . The drug candidate is formulated as film coated tablet and administered through oral route. BIIB050 is the chirally pure form of dexpramipexole. It was also under development for amyotrophic lateral sclerosis (ALS) and chronic rhinosinusitis.

Areteia Therapeutics overview

Areteia Therapeutics is a biotechnology company developing dexpramipexole, an oral medicine that inhibits the maturation of eosinophils. Areteia Therapeutics is headquartered in Bernardsville, New Jersey, the US.

Quick View Dexpramipexole dihydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Dexpramipexole dihydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Ear Nose Throat Disorders
  • Hematological Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.